AtriCure, Inc. $ATRC Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. lessened its position in AtriCure, Inc. (NASDAQ:ATRC) by 71.1% during the first quarter, Holdings Channel reports. The institutional investor owned 9,570 shares of the medical device company’s stock after selling 23,570 shares during the quarter. Bessemer Group Inc.’s holdings in AtriCure were worth $273,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after buying an additional 62,861 shares during the last quarter. Wellington Management Group LLP lifted its position in AtriCure by 8.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after purchasing an additional 322,818 shares during the period. First Light Asset Management LLC grew its position in shares of AtriCure by 32.0% during the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after buying an additional 285,083 shares during the period. GW&K Investment Management LLC grew its stake in AtriCure by 10.6% in the fourth quarter. GW&K Investment Management LLC now owns 952,089 shares of the medical device company’s stock valued at $37,665,000 after acquiring an additional 91,054 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in AtriCure by 8.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 921,897 shares of the medical device company’s stock worth $36,472,000 after purchasing an additional 71,341 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Stock Performance

Shares of AtriCure stock opened at $35.04 on Monday. The firm has a market capitalization of $1.77 billion, a P/E ratio of 166.87 and a beta of 1.24. The business’s fifty day simple moving average is $30.05 and its 200 day simple moving average is $31.36. The company has a current ratio of 4.29, a quick ratio of 3.18 and a debt-to-equity ratio of 0.15. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $43.18.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.37%. During the same period in the previous year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts anticipate that AtriCure, Inc. will post 0.13 EPS for the current year.

Insider Activity at AtriCure

In related news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the transaction, the director directly owned 26,373 shares of the company’s stock, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ATRC shares. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Canaccord Genuity Group lifted their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings downgraded AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. Raymond James Financial set a $52.00 target price on AtriCure in a research report on Tuesday, July 21st. Finally, Zacks Research cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.12.

Key Headlines Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Q2 earnings of $0.18 per share beat the $0.03 consensus and improved from a loss a year ago, showing a meaningful profitability turnaround. AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue of $153.6 million topped Wall Street estimates of $151.8 million, reinforcing that demand remains solid. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company lifted FY2026 EPS guidance to $0.24-$0.32, well above the prior consensus, and revenue guidance of $602 million-$610 million is also near or slightly above expectations. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management described the quarter as one of “healthy growth” and a “significant step up in profitability,” which supports the recent stock strength. AtriCure Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Short-interest data showed 0 reported shares, so it does not appear to be a meaningful trading catalyst.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.